NICE requests yet more information from Roche about Zelboraf for skin cancer
This article was originally published in Scrip
Executive Summary
In its latest draft guidance, NICE, the health technology appraisal institute for England and Wales, has once again requested Roche to provide further information on vemurafenib (Zelboraf) with the Institutes committee still "minded not to recommend vemurafenib for the treatment of unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma".